These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35542993)

  • 21. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
    Vaz M; Silva V; Monteiro C; Silvestre S
    Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
    Ross EL; Weinberg MS; Arnold SE
    JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease.
    Wang D; Kowalewski EK; Koch G
    Ther Innov Regul Sci; 2022 May; 56(3):501-516. PubMed ID: 35320578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alzheimer disease neuropathology in a patient previously treated with aducanumab.
    Plowey ED; Bussiere T; Rajagovindan R; Sebalusky J; Hamann S; von Hehn C; Castrillo-Viguera C; Sandrock A; Budd Haeberlein S; van Dyck CH; Huttner A
    Acta Neuropathol; 2022 Jul; 144(1):143-153. PubMed ID: 35581440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities.
    Sima DM; Phan TV; Van Eyndhoven S; Vercruyssen S; Magalhães R; Liseune A; Brys A; Frenyo P; Terzopoulos V; Maes C; Guo J; Hughes R; Gabr RE; Huijbers W; Saha-Chaudhuri P; Curiale GG; Becker A; Belachew S; Van Hecke W; Ribbens A; Smeets D
    JAMA Netw Open; 2024 Feb; 7(2):e2355800. PubMed ID: 38345816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
    Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
    J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.
    Day GS; Scarmeas N; Dubinsky R; Coerver K; Mostacero A; West B; Wessels SR; Armstrong MJ
    Neurology; 2022 Apr; 98(15):619-631. PubMed ID: 35197360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials.
    Wu W; Ji Y; Wang Z; Wu X; Li J; Gu F; Chen Z; Wang Z
    Eur J Med Res; 2023 Nov; 28(1):544. PubMed ID: 38017568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
    Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
    J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
    Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
    Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
    Villain N; Planche V; Levy R
    Rev Neurol (Paris); 2022 Dec; 178(10):1011-1030. PubMed ID: 36184326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-β-Amyloid Immunotherapy: A Meta-analysis.
    Jeong SY; Suh CH; Shim WH; Lim JS; Lee JH; Kim SJ
    Neurology; 2022 Nov; 99(19):e2092-e2101. PubMed ID: 36038268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
    Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
    Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.
    Martens RM; Bechten A; Ingala S; van Schijndel RA; Machado VB; de Jong MC; Sanchez E; Purcell D; Arrighi MH; Brashear RH; Wattjes MP; Barkhof F
    Eur Radiol; 2018 Mar; 28(3):1215-1226. PubMed ID: 28956123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications.
    Doran SJ; Sawyer RP
    Front Neurosci; 2024; 18():1326784. PubMed ID: 38312931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
    Jeremic D; Navarro-López JD; Jiménez-Díaz L
    Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria.
    Togher Z; Dolphin H; Russell C; Ryan M; Kennelly SP; O'Dowd S
    Int J Geriatr Psychiatry; 2022 Aug; 37(8):. PubMed ID: 35861223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies.
    Wasielewska JM; Chaves JCS; Johnston RL; Milton LA; Hernández D; Chen L; Song J; Lee W; Leinenga G; Nisbet RM; Pébay A; Götz J; White AR; Oikari LE
    Theranostics; 2022; 12(16):6826-6847. PubMed ID: 36276649
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.